2024年McDonald标准在疑似多发性硬化患者中的性能评估
2017年McDonald标准前瞻性应用,2024年标准回顾性应用。在274例患者中,2024标准较2017标准在初始检查后(220 vs 172)和末次随访时(237 vs 204)诊断更多MS,中位诊断时间更短(40 vs 84天),敏感性高(92.6%)但特异性中等(57.8%)。
要点
- 2024年McDonald标准较2017标准可更早诊断多发性硬化。
- 2024标准敏感性高(92.6%)但特异性中等(57.8%)。
- 2024标准在儿童和老年患者中性能相似。
核心结论
- 使用2024年McDonald标准可实现更早的多发性硬化诊断,但诊断频率更高,包括放射学孤立综合征患者。
- 修订后的标准在整个生命周期中性能相似。
研究设计与样本
- 所有患者完成脑和脊髓MRI最低诊断评估,2017年McDonald标准前瞻性应用,2024年标准回顾性应用。
- 排除73例(21%)其他疾病患者后,对274例患者进行分析。
主要发现
- 初始诊断检查后,2024标准诊断MS 220例,2017标准诊断172例(p < 0.01)。
- 末次随访时,2024标准诊断MS 237例,2017标准诊断204例(p < 0.01)。
- 2024标准中位诊断时间40天,2017标准84天(p < 0.01)。
- 2024标准初始检查后诊断性能:敏感性92.6%(95% CI 88.1%-95.8%),准确性83.6%(95% CI 78.7%-87.8%),特异性57.8%(95% CI 45.4%-69.4%),参考标准为末次随访时2017标准诊断MS。
- 诊断率增加和诊断性能在儿童(<18岁)和老年人(>50岁)中相似。
关键数值与推荐
- 2024年McDonald标准在初始诊断检查后诊断MS的敏感性为92.6%(95% CI 88.1%-95.8%),准确性为83.6%(95% CI 78.7%-87.8%),特异性为57.8%(95% CI 45.4%-69.4%)。
- 2024标准诊断MS的中位时间为40天,2017标准为84天(p < 0.01)。
临床怎么用
- 2024年McDonald标准可用于疑似多发性硬化患者的早期诊断,但需注意其特异性中等,可能增加放射学孤立综合征的诊断。
- 在儿童和老年患者中应用2024标准时诊断性能相似。
局限性
- 缺乏中心静脉征和kappa游离轻链数据。
- 部分患者缺少视神经评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The 2024 McDonald criteria provide new recommendations for multiple sclerosis (MS) diagnosis, but validation of the criteria is lacking. We wanted to investigate the application and performance of the 2024 McDonald criteria in patients with suspected MS seen in routine clinical practice. METHODS: We retrospectively identified patients referred with clinical and/or radiologic suspicion for MS between January and December 2024. All patients had a minimum diagnostic evaluation with brain and spinal cord MRI. The 2017 McDonald criteria were applied prospectively, and the 2024 McDonald criteria were applied retrospectively after the initial diagnostic workup and at last follow-up. We investigated (1) the number of patients diagnosed with MS using the 2017 McDonald criteria or the 2024 McDonald criteria, and (2) the diagnostic performance of the 2024 McDonald criteria when applied during the initial diagnostic workup, with an MS diagnosis using the 2017 McDonald criteria as the reference-standard. RESULTS: In 347 patients (mean age 39.4 years, 66% female) with suspected MS followed up for mean 15.3 (range 8-20) months, 73 (21%) had alternative disorders and were excluded. After applying the 2024 McDonald criteria in the remaining 274 patients, more patients were diagnosed with MS after the initial diagnostic workup (220 vs 172, p < 0.01), and at follow-up (237 vs 204, p < 0.01), compared with the 2017 McDonald criteria, and fewer patients were diagnosed with clinically or radiologically isolated syndrome. The median time to diagnosis was 40 vs 84 days (p < 0.01), respectively. After initial diagnostic workup, the 2024 McDonald criteria demonstrated high sensitivity (92.6%, 95% CI 88.1%-95.8%) and accuracy (83.6%, 95% CI 78.7%-87.8%), for an MS diagnosis using 2017 McDonald criteria at last follow-up, but moderate specificity (57.8%, 95% CI 45.4%-69.4%). The increased rate of MS diagnosis and the diagnostic performance of the revised criteria was similar in children (<18 years) and older adults (>50 years). DISCUSSION: Use of the 2024 McDonald allows for earlier MS diagnosis, but also more frequent diagnosis including in patients with radiologically isolated syndrome. The revised criteria have similar performance across the lifespan. Limitations include the lack of data on central vein sign and kappa free light chains, and missing optic nerve assessment in some patients.
引用
- Brownlee WJ, Maccarrone D, Nistri R, et al. Performance of the 2024 McDonald Criteria in Patients Under Evaluation for Suspected Multiple Sclerosis. Neurology. 2026. PMID: 41687049. doi:10.1212/WNL.0000000000214688
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。